Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08GIM
|
||||
| Former ID |
DIB013107
|
||||
| Drug Name |
Elisidepsin
|
||||
| Synonyms |
Irvalec; Elisidepsin trifluoroacetate; PM-02734; Erbb3 tyrosine kinase receptor inhibitor (cancer), PharmaMar; Kahalalide therapy (solid tumor), PharmaMar
|
||||
| Indication | Psoriasis [ICD9: 696; ICD10:L40] | Phase 2 | [1] | ||
| Company |
PharmaMar SA
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C77H125F3N14O18
|
||||
| Canonical SMILES |
N1(C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(<br />=O)CC[C@H](CC)C)C(C)C)[C@H](O)C)C(C)C)C(C)C)[C@@H](C(=O<br />)N[C@H](C(=O)N[C@@H](C(=O)N[C@H]2C(=O)N[C@@H](C(=O)N[C@<br />@H](C(=O)N[C@H](C(=O)N/C(=C\C)/C(=O)N[C@H](C(=O)O[C@@H]<br />2C)C(C)C)Cc2ccccc2)C(C)C)[C@H](CC)C)[C@H](CC)C)CCCN)CCC<br />1
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-3 | Target Info | Inhibitor | [2] | |
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| Endocytosis | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| Pathway Interaction Database | ErbB2/ErbB3 signaling events | ||||
| ErbB receptor signaling network | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| WikiPathways | ErbB Signaling Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Signaling Pathways in Glioblastoma | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Heart Development | |||||
| References | |||||
| REF 1 | First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug;33(4):901-10. | ||||
| REF 2 | Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.